Author:
Bedossa Pierre,Kleiner David E.
Publisher
Springer International Publishing
Reference144 articles.
1. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis. 2012;32:3–13.
2. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54:344–53.
3. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.
4. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–8.
5. Zimmerman HJ, Mac MF, Rappaport H, Alpert LK. Studies on the liver in diabetes mellitus. II. The significance of fatty metamorphosis and its correlation with insulin sensitivity. J Lab Clin Med. 1950;36:922–8.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Hepatocellular carcinoma—An updated review;Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma;2022
2. Inhibition of
miR‐499‐5p
expression improves nonalcoholic fatty liver disease;Annals of Human Genetics;2020-01-20
3. Alcoholic Liver Disease;Schiff's Diseases of the Liver;2017-10-23